NeoPharm (NEOL) Requests Hearing for Continued Listing on NASDAQ
More News related to NEOL
- NeoPharm Presents the Phase II Data of Liposome-Entrapped Paclitaxel (LEP) in Patients with Metastatic Breast Cancer
- NeoPharm Announces IND Filing for IL13-PE38QQR for the Treatment of Idiopathic Pulmonary Fibrosis
- NeoPharm (NEOL) Posts Q3 Loss of $0.06
- NeoPharm (NEOL) Requests Hearing for Continued Listing on NASDAQ
- NeoPharm (NEOL) Begins Enrollment for Phase II Trial of Liposomal Paclitaxel
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
NeoPharm, Inc. (NASDAQ: NEOL) intends to request a hearing before the NASDAQ Listing Qualifications Panel at which it will request continued listing on The NASDAQ Stock Market pending completion of its plan to regain compliance with the $1.00 bid price requirement, as set forth in NASDAQ Marketplace Rule 4310(c)(4). As previously announced on June 12, 2008, the NASDAQ Listing Qualifications Staff previously determined to grant the Company's request to transfer the listing of its common stock from The NASDAQ Global Market to The NASDAQ Capital Market. Based on discussions with the Staff, the Company believed it would be eligible for an additional 180-day grace period to regain compliance with the $1.00 bid price requirement, through December 20, 2008.[SM]
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
